The data will be submitted for regulatory approval next year to the U.S. Food and Drug Administration , Novartis said.

Dow Jones Newswires: Novartis prostate cancer drug trial meets primary endpoint
by
Tags:

The data will be submitted for regulatory approval next year to the U.S. Food and Drug Administration , Novartis said.
by
Tags: